Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Cancer Res CAN-21-3186.

DOI: https://doi.org/10.1158/0008-5472.CAN-21-3186

Published: 11 August 2022

View article

Includes: Supplementary data

Journal Articles

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Chia Chia Liu, Lanfang Qin, Carmine De Angelis, Sarmistha Nanda, Resel Pereira, Martin J. Shea, Agostina Nardone, Rinath Jeselsohn, Ofir Cohen, Nikhil Wagle, Zhijie Liu, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff, Xiaoyong Fu

Cancer Res (2022) 82 (4_Supplement): PD1-05.

DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD1-05

Published: 15 February 2022

View article

Journal Articles

Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery

Hariprasad Thangavel, Yingmin Zhu, Kurt R. Christensen, Xiaoyong Fu, Dean Edwards, Rachel Schiff, Meghana V. Trivedi

Cancer Res (2021) 81 (13_Supplement): 930.

DOI: https://doi.org/10.1158/1538-7445.AM2021-930

Published: 01 July 2021

View article

Journal Articles

Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Xiaoyong Fu, Resel Pereira, Lanfang Qin, Carmine De Angelis, Sarmistha Nanda, Martin Shea, Agostina Nardone, Rinath Jeselsohn, Ofir Cohen, Nikhil Wagle, Mothaffar Rimawi, C Kent Osborne, Rachel Schiff

Cancer Res (2021) 81 (4_Supplement): PD8-03.

DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD8-03

Published: 15 February 2021

View article

Journal Articles

Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)

Vidyalakshmi Sethunath, Xiaoyong Fu, Pamela L Luna, Sarmistha Nanda, Martin Shea, Jamunarani Veeraraghavan, Carmine De Angelis, Huizhong Hu, Chad Shaw, Mothaffar Rimawi, C. Kent Osborne, Rachel Schiff

Cancer Res (2021) 81 (4_Supplement): PS5-29.

DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS5-29

Published: 15 February 2021

View article

Journal Articles

Abstract 3508: FOXA1 genetic alterations in whites versus blacks or African Americans in breast and prostate cancer

Jennifer Torres, Hariprasad Thangavel, Xiaoyong Fu, Rachel Schiff, Meghana V. Trivedi

Cancer Res (2020) 80 (16_Supplement): 3508.

DOI: https://doi.org/10.1158/1538-7445.AM2020-3508

Published: 15 August 2020

View article

Journal Articles

Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

Cancer Res (2020) 80 (4_Supplement): GS2-01.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-GS2-01

Published: 15 February 2020

View article

Journal Articles

Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer

Carmine De Angelis, Maria Letizia Cataldo, Agostina Nardone, Jamunarani Veeraraghavan, Xiaoyong Fu, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Resel Pereira, Britta Weigelt, Jorge S. Reis-Filho, Mothaffar F. Rimawi, Rinath Jeselsohn, Kent Osborne, Rachel Schiff

Cancer Res (2020) 80 (4_Supplement): PD2-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-PD2-02

Published: 15 February 2020

View article

Journal Articles

Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer

Xiaoyong Fu, Resel Pereira, Carmine De Angelis, Sarmistha Nanda, Lanfang Qin, Jamunarani Veeraraghavan, Pier Selenica, Britta Weigelt, Jorge S Reis-Filho, Agostina Nardone, Rinath Jeselsohn, Myles Brown, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff

Cancer Res (2020) 80 (4_Supplement): PD7-01.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-PD7-01

Published: 15 February 2020

View article

Journal Articles

Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer

Xiaoyong Fu, Resel Pereira, Carmine De Angelis, Sarmistha Nanda, Lanfang Qin, Martin J Shea, Tamika Mitchell, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Carolina Gutierrez, Balázs Győrffy, Ofir Cohen, Nikhil Wagle, Agostina Nardone, Rinath Jeselsohn, Myles Brown, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff

Cancer Res (2020) 80 (4_Supplement): P6-04-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P6-04-02

Published: 15 February 2020

View article

Journal Articles

Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies

Rachel Schiff, Jamunarani Veeraraghavan, Xiaoyong Fu

Cancer Res (2018) 78 (13_Supplement): SY01-01.

DOI: https://doi.org/10.1158/1538-7445.AM2018-SY01-01

Published: 01 July 2018

View article

Journal Articles

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis

Cancer Res (2018) 78 (3): 671–684.

DOI: https://doi.org/10.1158/0008-5472.CAN-17-1327

Published: 31 January 2018

View article

Includes: Supplementary data

Journal Articles

Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models

Agostina Nardone, Amit Goldstein, Martin J. Shea, Tamika Mithchell, Xiaoyong Fu, Carmine De Angelis, Huizhong Hu, Xiaowei Xu, Mahitha Rajendran, Mark O'Connor, Gershon Locker, Susan Hilsenbeck, Kent Osborne, Rachel Schiff

Cancer Res (2015) 75 (15_Supplement): LB-166.

DOI: https://doi.org/10.1158/1538-7445.AM2015-LB-166

Published: 01 August 2015

View article

Journal Articles

Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination

Agostina Nardone, Gladys Morrison, Xiaoyong Fu, Martin Shea, Tamika Mitchell, Teresa Klinowska, C Kent Osborne, Rachel Schiff

Cancer Res (2015) 75 (9_Supplement): P3-05-03.

DOI: https://doi.org/10.1158/1538-7445.SABCS14-P3-05-03

Published: 01 May 2015

View article

Journal Articles

Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells

Cancer Res (2015) 75 (9_Supplement): P3-05-13.

DOI: https://doi.org/10.1158/1538-7445.SABCS14-P3-05-13

Published: 01 May 2015

View article

Journal Articles

Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8

Xiaoyong Fu, Rinath Jeselsohn, Emporia F Hollingsworth, Dolores Lopez-Terrada, Chad J Creighton, Agostina Nardone, Martin Shea, Laura M Heiser, Pavana Anur, Nicholas Wang, Catie Grasso, Paul Spellman, Carolina Gutierrez, Mothaffar F Rimawi, Susan G Hilsenbeck, Joe W Gray, Myles Brown, C K Osborne, Rachel Schiff

Cancer Res (2015) 75 (9_Supplement): PD6-2.

DOI: https://doi.org/10.1158/1538-7445.SABCS14-PD6-2

Published: 01 May 2015

View article

Journal Articles

Abstract 2290: Crosstalk between ER and PI3K signaling pathways in human luminal type breast cancer and its therapeutic implications

Xiaoyong Fu, Sarmistha Nanda, Ryan M. Gillihan, Martin Shea, Chad J. Creighton, Susan G. Hilsenbeck, Adrian V. Lee, Rachel Schiff, Kent C. Osborne

Cancer Res (2011) 71 (8_Supplement): 2290.

DOI: https://doi.org/10.1158/1538-7445.AM2011-2290

Published: 15 April 2011

View article

NARROW

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery

Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)

Abstract 3508: FOXA1 genetic alterations in whites versus blacks or African Americans in breast and prostate cancer

Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer

Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer

Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer

Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis

Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models

Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination

Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells

Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8

Abstract 2290: Crosstalk between ER and PI3K signaling pathways in human luminal type breast cancer and its therapeutic implications

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only